Document Detail

Cinacalcet is effective in relapses of secondary hyperparathyroidism after parathyroidectomy.
MedLine Citation:
PMID:  17449495     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Relapses of secondary hyperparathyroidism (SHPTH) after parathyroidectomy (PTx) in haemodialysis patients are relatively frequent. Calcimimetics (cinacalcet HCl) offer a new therapeutic opportunity for their treatment. However, no data about the treatment with cinacalcet of relapses of SHPTH after PTx are available in literature. The aim of this single-centre prospective study was to evaluate the therapeutic efficacy of cinacalcet in this high-risk category of patients.
METHODS: Twelve haemodialysis patients of our Dialysis Unit had a relapse of SHPTH after PTx, defined as serum levels of immunoreactive intact parathyroid hormone (iPTH)>300 pg/ml. They were stratified into a treatment group (the six patients having the highest serum levels of iPTH) and a control group (the remaining six patients): the former were treated for 6 months with a dose of cinacalcet ranging from 30 mg every other day to 60 mg a day; the latter continued to be administered the conventional treatment. Serum levels of albumin, iPTH, calcium (Ca), phosphate (P) and alkaline phosphatase were determined monthly. The treatment group included four cases of nodular hyperplasia and two cases of carcinoma of parathyroid glands, whereas the control group included four cases of nodular hyperplasia and two cases of diffuse hyperplasia.
RESULTS: At the start of the study, the six patients treated with cinacalcet showed a more severe picture of biochemical abnormalities when compared with the control patients. After 6 months of treatment, a statistically significant reduction in the serum levels of iPTH, Ca, P and CaxP product was obtained only in the patients treated with cinacalcet. Symptomatic episodes of hypocalcaemia (serum Ca<7.0 mg/dl) were observed in three patients of this group. The six patients undergoing the conventional treatment showed at 6 months a not significant decrease in the mean serum levels of iPTH and a not significant increase in the mean serum levels of Ca, P and CaxP product, when compared with the baseline values.
CONCLUSIONS: Our single-centre prospective study, even though small and of short duration, shows that cinacalcet is effective also in controlling relapses of SHPTH after PTx, thus representing a solid, and sometimes unique, therapeutic opportunity for this high-risk category of patients.
Carlo Lomonte; Maurizio Antonelli; Nicola Losurdo; Giovanni Marchio; Bernardo Giammaria; Carlo Basile
Related Documents :
8306465 - Postoperative studies on parathyroid hormone secretion in patients operated on for prim...
16464885 - Application of nkf-k/doqi clinical practice guidelines for bone metabolism and disease:...
16517535 - In vitro effects of vitamin c and selenium on nk activity of patients with beta-thalass...
3954265 - Is serum parathormone assay necessary in evaluating primary hyperparathyroidism?
23196515 - Whether or not als lesions spread contiguously?
17852215 - The usage of functional wrist orthoses in patients with rheumatoid arthritis.
Publication Detail:
Type:  Journal Article     Date:  2007-04-20
Journal Detail:
Title:  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association     Volume:  22     ISSN:  0931-0509     ISO Abbreviation:  Nephrol. Dial. Transplant.     Publication Date:  2007 Jul 
Date Detail:
Created Date:  2007-07-02     Completed Date:  2007-10-16     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  8706402     Medline TA:  Nephrol Dial Transplant     Country:  England    
Other Details:
Languages:  eng     Pagination:  2056-62     Citation Subset:  IM    
Division of Nephrology, Miulli General Hospital, Acquaviva delle Fonti, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Calcium / blood
Hyperparathyroidism, Secondary / blood,  drug therapy*,  surgery*
Hypocalcemia / chemically induced
Middle Aged
Naphthalenes / adverse effects,  therapeutic use*
Parathyroid Hormone / blood
Phosphorus / blood
Prospective Studies
Treatment Outcome
Reg. No./Substance:
0/Naphthalenes; 0/Parathyroid Hormone; 7440-70-2/Calcium; 7723-14-0/Phosphorus; UAZ6V7728S/cinacalcet

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pyridoxal phosphate prevents progression of diabetic nephropathy.
Next Document:  Insulin maintains plasma antioxidant capacity at an early phase of kidney transplantation.